What is the standard of care for locally advanced Pancreatic Cancer according to NCCN guidelines

Standard of Care for Locally Advanced Pancreatic Cancer (NCCN Guidelines)

Based on the NCCN Guidelines Version 2.2025 for Pancreatic Adenocarcinoma, the standard of care for locally advanced pancreatic cancer depends on your performance status (how well you can tolerate treatment) and involves several key approaches:

PRIMARY TREATMENT OPTIONS

For Patients in Good or Intermediate Performance Status:

First-line therapy typically includes:

1. Induction Chemotherapy (preferred approach)

   • 4-6 months of systemic chemotherapy given first
   • Followed by chemoradiation (chemotherapy combined with radiation therapy)
   • OR stereotactic body radiation therapy (SBRT) in selected patients

2. Chemoradiation Alone

   • For patients who cannot tolerate induction chemotherapy

3. SBRT (Stereotactic Body Radiation Therapy)

   • In selected patients with locally advanced disease and no distant metastases
   • Used if induction chemotherapy is not an option

4. Clinical Trials (preferred option when available)

For Patients in Poor Performance Status:

• Palliative and best supportive care
• Consider single-agent chemotherapy or palliative radiation therapy

IMPORTANT DIAGNOSTIC WORKUP BEFORE TREATMENT

According to NCCN Guidelines, before starting treatment, you should have:

• Molecular profiling of tumor tissue using next-generation sequencing (NGS) to identify actionable mutations including:

  • KRAS mutations
  • BRCA1/2 mutations
  • PALB2 mutations
  • Fusions (ALK, NTRK, ROS1, FGFR2, RET)
  • Microsatellite instability (MSI) or mismatch repair deficiency (dMMR)
  • Tumor mutational burden (TMB)

• Genetic testing for inherited mutations (germline testing) - recommended for ALL pancreatic cancer patients

• Complete staging with chest and pelvis CT imaging

WHAT HAPPENS AFTER INITIAL TREATMENT

According to NCCN Guidelines, after induction chemotherapy:

• If there is marked radiographic improvement: You should be referred to a high-volume center for consideration of surgery
• If there is radiographic stability with clinical improvement or decline in CA 19-9 marker: Still consider surgical evaluation
• If disease progresses: Continue with systemic therapy or consider palliative care

KEY PRINCIPLE: MULTIDISCIPLINARY APPROACH

The NCCN Guidelines emphasize that decisions about treatment should involve multidisciplinary consultation at a high-volume center with expertise from:

• Medical oncology
• Radiation oncology
• Surgery
• Pathology
• Palliative care
• Genetic counseling

EMERGING PRECISION MEDICINE APPROACH

According to recent expert guidance from Dr. [removed] Strickler (Duke University), pancreatic cancer treatment is evolving toward precision medicine—tailoring treatment based on your tumor's specific genetic mutations. This means:

• Targeted therapies may be available based on your molecular profiling results
• New KRAS inhibitors show promise for the 87% of pancreatic cancers with KRAS mutations
• Treatment selection increasingly depends on your individual tumor's genetic profile, not just standard chemotherapy

IMPORTANT NOTES

⚠️ Important distinction: The NCCN Guidelines note that based on the LAP-07 trial data, there is no clear survival benefit with conventional chemoradiation following gemcitabine monotherapy alone. This is why induction chemotherapy followed by chemoradiation is now preferred over chemoradiation alone.

Questions to ask your oncology team:

1. What is my performance status, and how does that affect my treatment options?
2. Has molecular profiling been done on my tumor? Can I see the report?
3. Have I been tested for inherited genetic mutations (germline testing)?
4. Am I a candidate for clinical trials?
5. Should I get a second opinion at a high-volume pancreatic cancer center?
6. If I respond well to induction chemotherapy, am I a candidate for surgery?
7. What are the specific chemotherapy regimens you're recommending, and why?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.